Patients must be eligible for neoadjuvant treatment (ipilimumab and nivolumab)
Patients must be 16 years of age or older.
Patients must have a histologically confirmed diagnosis of macroscopic resectable stage III melanoma (stage III B/C/D) with one or more macroscopic lymph node metastase defined as either one:
a palpable node, confirmed as melanoma by pathology; a non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis), confirmed as melanoma by pathology;
a PET scan positive lymph node of any size confirmed as melanoma by pathology;
The patient must have a measurable tumor burden that qualifies (according to clinical practice) for neoadjuvant therapy with immune checkpoint inhibitors
Patients in whom ILN marking is feasible
Written informed consent
You may not be if
Uveal/ocular or mucosal melanoma
WHO performance status of two or more
In-transit metastases only (without cytological or histological proven lymph node involvement)
Prior targeted therapy targeting BRAF and/or MEK for melanoma
Prior immunotherapy targeting CTLA-4, PD-1 or PD-L1 for melanoma
Patients with (history of) distant metastasis (stage IV melanoma)
Clareo Health | Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
